-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70

Benzinga·10/02/2026 09:36:11
Morgan Stanley analyst Sean Laaman initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $70.